- •Sporadic Creutzfeldt-Jakob disease (sCJD) is a transmissible, progressive, neurodegenerative disease.
- •The clinical features of sCJD include rapidly progressive cognitive decline, myoclonus, visual or cerebellar symptoms, pyramidal or extrapyramidal signs, and akinetic mutism.
- •Diagnostic tools of sCJD include electroencephalography, brain magnetic resonance imaging, cerebrospinal fluid 14-3-3 protein level, and real-time quaking-induced conversion assay.
- •Intestinal pseudo-obstruction has been observed in patients with sCJD, but the relationship between sCJD and autonomic nervous system dysfunction is unclear.
Creutzfeldt-Jakob disease (CJD) is a transmissible, progressive, neurogenerative disease that carries a uniformly poor prognosis. It is caused by an accumulation of misfolded prions that affect the structural conformation of the surrounding proteins. Sporadic CJD is the most common form of CJD, accounting for 85% to 95% of all CJD cases. The rarity of CJD makes its diagnosis challenging, and it can mimic other neurologic conditions. The CJD International Surveillance Network diagnostic criteria include clinical features and diagnostic findings with which health care providers should be familiar. The purpose of this report is to present a case of postmortem definite CJD.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal for Nurse Practitioners
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Validation of revised international Creutzfeldt-Jakob disease surveillance network diagnostic criteria for sporadic Creutzfeldt-Jakob disease.JAMA Netw Open. 2022; 5e2146319https://doi.org/10.1001/jamanetworkopen.2021.46319
- Laboratory diagnosis of Creutzfeldt-Jakob disease.N Engl J Med. 2022; 386: 1345-1350https://doi.org/10.1056/NEJMra2119323
- Sporadic and familial CJD: classification and characterization.Br Med Bull. 2003; 66: 213-239https://doi.org/10.1093/bmb/66.1.213
- Analysis of clinical features, diagnostic tests, and biomarkers in patients with suspected Creutzfeldt-Jakob disease, 2014-2021.JAMA Netw Open. 2022; 5e2225098https://doi.org/10.1001/jamanetworkopen.2022.25098
- Intestinal pseudo-obstruction in Creutzfeldt-Jakob disease.Clin Auton Res. 2021; 31: 795-797https://doi.org/10.1007/s10286-021-00817-2
- Diagnostic criteria for surveillance of CJD from 1 January 2017.(Updated 2021)https://www.eurocjd.ed.ac.uk/node/833Date accessed: October 25, 2022
- Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance.Neurology. 2018; 91: e331-e338https://doi.org/10.1212/WNL.0000000000005860
- Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.Lancet Neurol. 2021; 20: 235-246https://doi.org/10.1016/S1474-4422(20)30477-4
- Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada.Neurology. 2005; 64: 1586-1591https://doi.org/10.1212/01.WNL.0000160117.56690.B2
Fnu Alfandy, DNP, AGACNP-BC, ANP-BC, is the Advanced Practice Provider Program manager at Stanford Health Care Neurosciences Service Line in Stanford, CA, and can be contacted at [email protected].
Hamid Reza Salari-Namin, MD, is a vascular neurologist at Eisenhower Health in Rancho Mirage, CA.
Dennis Kaighn Constan, PharmD, MBC, BCPS, is a clinical pharmacist at Eisenhower Health.
Published online: February 02, 2023
In compliance with standard ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.
© 2022 Elsevier Inc. All rights reserved.